Inside Cornerstone Robotics' Sentire® System: A New Challenger in Global Surgical Robotics

The Sentire system's regulatory portfolio as of mid-2026 grants it access to three major markets:

• China (NMPA): Cornerstone Robotics obtained approval from China's National Medical Products Administration in September 2024, enabling domestic commercial sales and providing the foundational market for its initial deployment .
• European Union / EEA (CE Mark under MDR): The certification received on May 25, 2026, under the EU's stringent Medical Device Regulation formally grants Sentire access to all 27 EU member states and European Economic Area countries . The company stated this milestone "affirms that its safety, efficacy, and quality management system fully complies with stringent EU requirements" .
• Singapore (HSA): The simultaneous HSA certification opens a strategic gateway into the Southeast Asian market .

Notably, no FDA clearance in the United States has been publicly confirmed as of mid-2026, leaving the world's largest medical device market outside Sentire's immediate commercial reach.

Clinical Scope and First European Deployment

The Sentire Endoscopic Surgical System is a teleoperated, multi-arm robotic platform designed for minimally invasive soft-tissue surgery across multiple specialties . Its cleared clinical applications include general surgery, urology, gynecology, and thoracic procedures . The system features a surgeon console and a 3D high-definition vision system, replicating the multi-port approach common among established market leaders.

Cornerstone Robotics initiated its first formal clinical investigation in Europe at Portsmouth Hospitals University NHS Trust (PHU) in the UK. This deployment of the Sentire C1000 model at Queen Alexandra Hospital, which began in mid-2025, represents a critical step in gathering the real-world clinical data needed to support broader adoption and future regulatory submissions .

Funding History: $270 Million to Fuel Commercialization

The company's rapid regulatory progress has been supported by two major disclosed funding rounds within eleven months:

• Series C — Early 2025 (~$70 million): Led by global investment organization EQT, with participation from Qiming Venture Partners, Alpha JWC Ventures, the Innovation and Technology Venture Fund, and others. The funds were earmarked for commercialization efforts, product development, clinical trials, and regulatory approvals .
• Oversubscribed Round — November 2025 (~$200 million): This round was anchored by the government-owned Hong Kong Investment Corporation (HKIC) and attracted a global strategic investor, sovereign wealth funds, and existing shareholders including Qiming Venture Partners and K2VC . The company stated the proceeds would primarily accelerate global commercialization and continued technological innovation .

Competitive Significance: Challenging the da Vinci Dynasty

Sentire enters a global surgical robotics market long dominated by Intuitive Surgical's da Vinci platform, which holds an estimated 71% market share . However, the competitive landscape has been shifting since 2024-2025 with the rise of credible alternatives, most notably Medtronic's modular Hugo RAS system and CMR Surgical's compact Versius platform .

Sentire's competitive positioning rests on several key factors:

• Modular Design and Access: The system features independent robotic arm carts, an architecture similar to Medtronic's Hugo RAS, which can offer greater flexibility in the operating room and potentially better abdominal access for general and colorectal surgeries .
• Geographic Strategy and Government Backing: As a Chinese-origin system with the HKIC as a lead investor, Sentire may be uniquely positioned to compete in cost-sensitive markets across Asia, the Middle East, and Eastern Europe where price competition against the da Vinci platform is a critical factor .
• Rapid Regulatory Pace: The company moved from its initial NMPA approval in China to dual European and Southeast Asian certifications in under 20 months, demonstrating an aggressive global regulatory strategy.

Significant challenges remain. The company has not yet published large-scale, peer-reviewed clinical trial data comparing its outcomes to established systems. Its current installed base is minimal compared to Intuitive's decades-long track record and the growing clinical evidence for competitors like the Hugo RAS system . Furthermore, the lack of FDA clearance keeps it from competing in the highly lucrative U.S. market. Sentire's competitive significance over the next two to three years will depend entirely on its ability to translate these regulatory wins into real-world clinical adoption and a robust body of published evidence.